Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

ClinicalTrials.gov ID: NCT05979779

Public ClinicalTrials.gov record NCT05979779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) during this time. The end-of-study visit will take place approximately 4 weeks after the last dose of the study drug (Week 30).

Study identification

NCT ID
NCT05979779
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Enrollment
219 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 4, 2023
Primary completion
Jan 20, 2025
Completion
May 31, 2025
Last update posted
Apr 17, 2025

2023 – 2025

United States locations

U.S. sites
20
U.S. states
6
U.S. cities
16
Facility City State ZIP Site status
ProSciento CRU Chula Vista California 91911
Velocity Clinical Research Los Angeles California 90057
Catalina Research Institute Montclair California 91763
Northern California Research Center Sacramento California 95821
Metro Clinical Trials San Bernardino California 92404
Synergy Healthcare Bradenton Florida 34208
ABMED Clinical Research Corp. Cape Coral Florida 33914
Southwest General Healthcare Center Fort Myers Florida 33907
Miami Clinical Research Miami Florida 33155
Advanced Clinical Research Miami Florida 33156
Century Research, LLC Miami Florida 33173
Entrust Clinical Research Miami Florida 33176
Panax Clinical Research Miami Lakes Florida 33014
Tandem Clinical Research Marrero Louisiana 70072
CenExel HRI Berlin New Jersey 08009
Lillestol Research Fargo North Dakota 58104
IMA Clinical Research-Austin Austin Texas 78745
Mt Olympus Medical Research Houston Texas 77030
Houston Research Institute Houston Texas 77079
Texas Liver Institute San Antonio Texas 78215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05979779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 17, 2025 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05979779 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →